Cases & Deals

BioMarin resolves patent infringement claims against Par Pharmaceutical related to Kuvan®

Clients BioMarin Pharmaceutical Inc.

Jones Day client BioMarin Pharmaceutical, Inc. successfully resolved a patent infringement action against Par Pharmaceutical, Inc. relating to the defendant's submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic version of Kuvan® (sapropterin dihydrocholride), the only FDA-approved treatment to reduce blood phenylalanine levels in persons with BH-4 responsive phenylketonuria (PKU).

BioMarin Pharmaceutical Inc. et al. v. Par Pharmaceutical, Inc., Case No. 3:15-cv-01706 (D.N.J.)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.